After manufacturing setback at FDA, Ascendis strikes $150M royalty deal on its first commercial drug
Fierce Pharma
SEPTEMBER 6, 2023
Royalty Pharma, a company known for ponying up chunks of cash in exchange for long-term drug royalties, has hopped on board with Ascendis Pharma's long-acting growth hormone Skytrofa. Ascendis hopes to bring its second TransCon product to the market and overcome manufacturing issues.
Let's personalize your content